← Leaderboards

Carl F Nathan

Weill Medical College Of Cornell Univ

Google Scholar ↗PubMed ↗ORCID ↗

$43,444,016

Attributed

$49,822,577

Total exposure

22

Grants

17

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $10.6M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$114,276,870 · 24

By mechanism

U19$61,295,345 · 4

P01$26,080,217 · 4

R01$18,910,326 · 6

UC1$3,397,889 · 1

R21$1,580,750 · 4

R33$1,100,630 · 1

Top collaborators

Michael Stephen Glickman25 shared
Kyu Y Rhee7 shared

Others in their field

Top investigators on “Mycobacterium Tuberculosis”

Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
Constance Ann Benson · University Of California, San Diego$150,079,712
Kevin Urdahl · Seattle Children'S Hospital$86,597,961
David Alland · Rutgers Biomedical And Health Sciences$70,943,567
Sarah Fortune · Harvard School Of Public Health$51,119,645
William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310

Research focus

Mycobacterium TuberculosisTuberculosisIn VitroInfectionGenesPharmaceutical PreparationsMacrophagePathogenPathway InteractionsResearch PersonnelTuberculosis TreatmentPhenotypeChemotherapyEnzymesCause Of DeathBaseCellsStressCommunicable DiseasesResponseMetabolicTuberculosis DrugsAnimal ModelRelapse

Grant awards (89)

Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck$3,019,448

P01 · FY2025 · AI

Project 1: Transmission Biology of M. tuberculosis: Genes Required to Survive Stressful Transitions$835,574

P01 · FY2025 · AI · contact PI

Targeted Degradation of Mycobacterial PknG for Host Control of Tuberculosis$254,250

R21 · FY2025 · AI · contact PI

Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck$3,048,982

P01 · FY2024 · AI

Project 1: Transmission Biology of M. tuberculosis: Genes Required to Survive Stressful Transitions$796,764

P01 · FY2024 · AI · contact PI

Mechanisms of macrophage death co-dependent on M. tuberculosis and IFN-a,b receptor$211,875

R21 · FY2024 · AI · contact PI

Tri-Institutional TRAC Developmental Core$87,912

P30 · FY2024 · AI · contact PI

Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck$3,076,114

P01 · FY2023 · AI

Project 1: Transmission Biology of M. tuberculosis: Genes Required to Survive Stressful Transitions$875,451

P01 · FY2023 · AI · contact PI

Tri-Institutional TRAC Developmental Core$409,550

P30 · FY2023 · AI · contact PI

Mechanisms of macrophage death co-dependent on M. tuberculosis and IFN-a,b receptor$254,250

R21 · FY2023 · AI · contact PI

Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck$3,188,803

P01 · FY2022 · AI

Project 1: Transmission Biology of M. tuberculosis: Genes Required to Survive Stressful Transitions$756,424

P01 · FY2022 · AI · contact PI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation$747,665

R01 · FY2022 · AI · contact PI

Tri-Institutional TRAC Developmental Core$415,346

P30 · FY2022 · AI · contact PI

Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck$235,997

P01 · FY2022 · AI

Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck$3,258,815

P01 · FY2021 · AI

Project 1: Transmission Biology of M. tuberculosis: Genes Required to Survive Stressful Transitions$763,384

P01 · FY2021 · AI · contact PI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation$747,665

R01 · FY2021 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$6,446,187

U19 · FY2020 · AI · contact PI

Viable but Nonculturable Mtb$947,618

U19 · FY2020 · AI · contact PI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation$747,665

R01 · FY2020 · AI · contact PI

Epidemiology of SARS-CoV-2 in Low-income Countries.$632,901

U19 · FY2020 · AI · contact PI

Administrative Core$537,471

U19 · FY2020 · AI · contact PI

Epidemiology of SARS-CoV-2 in Low-income Countries.$353,106

U19 · FY2020 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$6,756,890

U19 · FY2019 · AI · contact PI

Viable but Nonculturable Mtb$1,436,684

U19 · FY2019 · AI · contact PI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation$625,684

R01 · FY2019 · AI · contact PI

Administrative Core$605,886

U19 · FY2019 · AI · contact PI

Mycobacterial Phosphopantetheine Hydrolase: Potential for Salvage of Coenzyme A$211,875

R21 · FY2019 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$6,663,767

U19 · FY2018 · AI · contact PI

Viable but Nonculturable Mtb$1,277,246

U19 · FY2018 · AI · contact PI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation$625,684

R01 · FY2018 · AI · contact PI

Administrative Core$507,593

U19 · FY2018 · AI · contact PI

Mycobacterial Phosphopantetheine Hydrolase: Potential for Salvage of Coenzyme A$254,250

R21 · FY2018 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$118,513

U19 · FY2018 · AI · contact PI

Viable but Nonculturable Mtb$118,513

U19 · FY2018 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$6,990,368

U19 · FY2017 · AI · contact PI

Viable but Nonculturable Mtb$1,246,465

U19 · FY2017 · AI · contact PI

Administrative Core$510,529

U19 · FY2017 · AI · contact PI

Targeting the Host to Treat TB: Inhibitors of Protein Kinase R$364,370

R33 · FY2017 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$7,215,105

U19 · FY2016 · AI · contact PI

Viable but Nonculturable Mtb$1,337,354

U19 · FY2016 · AI · contact PI

Administrative Core$530,864

U19 · FY2016 · AI · contact PI

Targeting the Host to Treat TB: Inhibitors of Protein Kinase R$364,370

R33 · FY2016 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$7,165,182

U19 · FY2015 · AI · contact PI

Viable but Nonculturable Mtb$1,581,787

U19 · FY2015 · AI · contact PI

Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb$920,600

R01 · FY2015 · AI · contact PI

Administrative Core$559,889

U19 · FY2015 · AI · contact PI

Targeting the Host to Treat TB: Inhibitors of Protein Kinase R$371,890

R33 · FY2015 · AI · contact PI

Tri-Institutional TB Research Unit: Persistence and Latency$6,284,115

U19 · FY2014 · AI · contact PI

Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb$920,600

R01 · FY2014 · AI · contact PI

Viable but Nonculturable Mtb$876,100

U19 · FY2014 · AI · contact PI

Administrative Core$595,212

U19 · FY2014 · AI · contact PI

Targeting the Host to Treat TB: Inhibitors of Protein Kinase R$192,852

R21 · FY2014 · AI · contact PI

Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb$865,364

R01 · FY2013 · AI · contact PI

Targeting the Host to Treat TB: Inhibitors of Protein Kinase R$201,398

R21 · FY2013 · AI · contact PI

Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb$919,954

R01 · FY2012 · AI · contact PI

Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb$876,693

R01 · FY2011 · AI · contact PI

Mycobacterial Proteasome Inhibitors$499,576

R56 · FY2010 · AI · contact PI

Targets in Mycobacterium Tuberculosis: Stress Resistance & Repair$883,176

R01 · FY2009 · AI · contact PI

Mycobacterial Proteasome Inhibitors$499,329

R56 · FY2009 · AI · contact PI

Targets in Mycobacterium Tuberculosis: Stress Resistance & Repair$861,514

R01 · FY2008 · AI · contact PI

MACROPHAGES, DENDRITIC CELLS AND PATHOGENS$1,364,588

P01 · FY2007 · AI · contact PI

Targets in Mycobacterium Tuberculosis: Stress Resistance & Repair$831,940

R01 · FY2007 · AI · contact PI

MACROPHAGES, DENDRITIC CELLS AND PATHOGENS$1,384,909

P01 · FY2006 · AI · contact PI

Targets in M. Tuberculosis:Stress Resistance & Repair$835,969

R01 · FY2006 · AI · contact PI

MACROPHAGES, DENDRITIC CELLS AND PATHOGENS$1,388,080

P01 · FY2005 · AI

Targets in M. Tuberculosis:Stress Resistance &Repair$655,344

R01 · FY2005 · AI

Dihydrolipoamide Acyltransferase:Target for Chemotherapy$3,397,889

UC1 · FY2004 · AI

MACROPHAGES, DENDRITIC CELLS AND PATHOGENS$1,344,411

P01 · FY2004 · AI

TARGETING DEFENSES OF MYCOBACTERIUM TUBERCULOSIS$535,064

R01 · FY2004 · HL

NEUTROPHIL ACTIVATION IN SEPSIS-- ROLE OF PYK2 PATHWAY$438,046

R01 · FY2004 · AI

ROLE OF NO SYNTHASE-2 IN MURINE ALZHEIMER'S DISEASE$254,250

R01 · FY2004 · AG

MACROPHAGES, DENDRITIC CELLS AND PATHOGENS$742,473

P01 · FY2003 · AI

TARGETING DEFENSES OF MYCOBACTERIUM TUBERCULOSIS$521,587

R01 · FY2003 · HL

MYCOBACTERIAL RESISTANCE TO REACTIVE NITROGEN/OXYGEN$500,362

R01 · FY2003 · HL

NEUTROPHIL ACTIVATION IN SEPSIS-- ROLE OF PYK2 PATHWAY$425,533

R01 · FY2003 · AI

ROLE OF NO SYNTHASE-2 IN MURINE ALZHEIMER'S DISEASE$254,250

R01 · FY2003 · AG

TARGETING DEFENSES OF MYCOBACTERIUM TUBERCULOSIS$508,500

R01 · FY2002 · HL

MYCOBACTERIAL RESISTANCE TO REACTIVE NITROGEN/OXYGEN$489,618

R01 · FY2002 · HL

NEUTROPHIL ACTIVATION IN SEPSIS-- ROLE OF PYK2 PATHWAY$413,139

R01 · FY2002 · AI

ROLE OF NO SYNTHASE-2 IN MURINE ALZHEIMER'S DISEASE$254,250

R01 · FY2002 · AG

MYCOBACTERIAL RESISTANCE TO REACTIVE NITROGEN/OXYGEN$479,186

R01 · FY2001 · HL

NEUTROPHIL ACTIVATION IN SEPSIS-- ROLE OF PYK2 PATHWAY$401,105

R01 · FY2001 · AI

ROLE OF NO SYNTHASE-2 IN MURINE ALZHEIMER'S DISEASE$254,250

R01 · FY2001 · AG

MYCOBACTERIAL RESISTANCE TO REACTIVE NITROGEN/OXYGEN$473,929

R01 · FY2000 · HL

NEUTROPHIL ACTIVATION IN SEPSIS-- ROLE OF PYK2 PATHWAY$387,490

R01 · FY2000 · AI

ROLE OF NO SYNTHASE-2 IN MURINE ALZHEIMER'S DISEASE$254,250

R01 · FY2000 · AG